Paolo Tarantino: In our recent Nature Review we suggested some strategies to mitigate toxicity of novel ADC

Paolo Tarantino, clinical research fellow at the Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Unfortunately true: novel ADCs are much more potent and effective than 1st gen ones, yet the higher potency comes at the cost of more chemo-related toxicities. In our recent Nature Review we suggested some strategies to mitigate toxicity of novel ADC

Optimize the dose and schedule. Randomized studies with T-DXd are showing that lowering the dose can reduce toxicity and retain efficacy in certain indications. Response-adapted strategies are being studied to adapt the dose based on the response to the regimen.

Develop smart monitoring devices. Many are in development to achieve a fast, easy and comfortable home monitoring of vital signs or other parameters that may allow for an early diagnosis (and better treatment) of ADC-related toxicities.

Develop a new generation of safer ADCs. This will likely need molecular adaptations in each ADC component: making the antibody more specific, optimizing linker stability and the tumor-specificity of the payload. Many innovative ADCs are being tested, the future is bright.”

For the article click here
Source: Paolo Tarantino/X